Request Demo
Recent blog posts
Latest Hotspot
8 min read
Relmapirazin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Relmapirazin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07659782 GFH-375 KRAS mutant Non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07659782, evaluating GFH-375 in KRAS mutant Non-small Cell Lung Cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Flurpiridaz F 18 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Flurpiridaz F 18: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07661329 Bimatoprost Glaucoma, Open-Angle Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07661329, evaluating Bimatoprost in Glaucoma, Open-Angle: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Suraxavir Marboxil Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Suraxavir Marboxil: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07661173 Carboplatin EGFR-mutated non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07661173, evaluating Carboplatin in EGFR-mutated non-small Cell Lung Cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Efsubaglutide Alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Efsubaglutide Alfa: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07659886 Vancomycin Hydrochloride Fractures, Open Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07659886, evaluating Vancomycin Hydrochloride in Fractures, Open: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07660094 Pembrolizumab metastatic non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07660094, evaluating Pembrolizumab in metastatic non-small cell lung cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Ebronucimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Ebronucimab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07658872 Sintilimab Locally Advanced Gastroesophageal Junction Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07658872, evaluating Sintilimab in Locally Advanced Gastroesophageal Junction Adenocarcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Avutometinib/Defactinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Avutometinib/Defactinib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.